These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 18006966

  • 1. Long term pharmacotherapy for obesity and overweight: updated meta-analysis.
    Rucker D, Padwal R, Li SK, Curioni C, Lau DC.
    BMJ; 2007 Dec 08; 335(7631):1194-9. PubMed ID: 18006966
    [Abstract] [Full Text] [Related]

  • 2. [Pharmacological therapy of obesity].
    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.
    G Ital Cardiol (Rome); 2008 Apr 08; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [Abstract] [Full Text] [Related]

  • 3. Long-term pharmacotherapy for obesity and overweight.
    Padwal R, Li SK, Lau DC.
    Cochrane Database Syst Rev; 2003 Apr 08; (4):CD004094. PubMed ID: 14584004
    [Abstract] [Full Text] [Related]

  • 4. Long-term pharmacotherapy for obesity and overweight.
    Padwal R, Li SK, Lau DC.
    Cochrane Database Syst Rev; 2004 Apr 08; 2003(3):CD004094. PubMed ID: 15266516
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A, Winterholer S, Jeitler K, Horvath K, Berghold A, Krenn C, Semlitsch T.
    Cochrane Database Syst Rev; 2021 Jan 17; 1(1):CD007654. PubMed ID: 33454957
    [Abstract] [Full Text] [Related]

  • 8. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K, Sundström J, Neovius K, Rössner S, Neovius M.
    Obes Rev; 2010 Nov 17; 11(11):777-91. PubMed ID: 20025693
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
    Viner RM, Hsia Y, Tomsic T, Wong IC.
    Obes Rev; 2010 Aug 17; 11(8):593-602. PubMed ID: 19922432
    [Abstract] [Full Text] [Related]

  • 10. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
    Johansson K, Neovius K, DeSantis SM, Rössner S, Neovius M.
    Obes Rev; 2009 Sep 17; 10(5):564-75. PubMed ID: 19460116
    [Abstract] [Full Text] [Related]

  • 11. Long-term effects of weight-reducing drugs in hypertensive patients.
    Siebenhofer A, Jeitler K, Horvath K, Berghold A, Siering U, Semlitsch T.
    Cochrane Database Syst Rev; 2013 Mar 28; (3):CD007654. PubMed ID: 23543553
    [Abstract] [Full Text] [Related]

  • 12. Rimonabant for the treatment of overweight and obese people.
    Burch J, McKenna C, Palmer S, Norman G, Glanville J, Sculpher M, Woolacott N.
    Health Technol Assess; 2009 Oct 28; 13 Suppl 3():13-22. PubMed ID: 19846024
    [Abstract] [Full Text] [Related]

  • 13. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.
    Ara R, Blake L, Gray L, Hernández M, Crowther M, Dunkley A, Warren F, Jackson R, Rees A, Stevenson M, Abrams K, Cooper N, Davies M, Khunti K, Sutton A.
    Health Technol Assess; 2012 Oct 28; 16(5):iii-xiv, 1-195. PubMed ID: 22340890
    [Abstract] [Full Text] [Related]

  • 14. Long-term effects of weight-reducing drugs in hypertensive patients.
    Siebenhofer A, Horvath K, Jeitler K, Berghold A, Stich AK, Matyas E, Pignitter N, Siering U.
    Cochrane Database Syst Rev; 2009 Jul 08; (3):CD007654. PubMed ID: 19588440
    [Abstract] [Full Text] [Related]

  • 15. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
    Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J.
    Cochrane Database Syst Rev; 2005 Jan 25; 2005(1):CD004096. PubMed ID: 15674929
    [Abstract] [Full Text] [Related]

  • 16. Weight management and current options in pharmacotherapy: orlistat and sibutramine.
    Leung WY, Thomas GN, Chan JC, Tomlinson B.
    Clin Ther; 2003 Jan 25; 25(1):58-80. PubMed ID: 12637112
    [Abstract] [Full Text] [Related]

  • 17. Drug interventions for the treatment of obesity in children and adolescents.
    Mead E, Atkinson G, Richter B, Metzendorf MI, Baur L, Finer N, Corpeleijn E, O'Malley C, Ells LJ.
    Cochrane Database Syst Rev; 2016 Nov 29; 11(11):CD012436. PubMed ID: 27899001
    [Abstract] [Full Text] [Related]

  • 18. Orlistat and sibutramine beyond weight loss.
    Mannucci E, Dicembrini I, Rotella F, Rotella CM.
    Nutr Metab Cardiovasc Dis; 2008 Jun 29; 18(5):342-8. PubMed ID: 17928208
    [Abstract] [Full Text] [Related]

  • 19. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.
    O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G.
    Health Technol Assess; 2001 Jun 29; 5(18):1-81. PubMed ID: 11399238
    [Abstract] [Full Text] [Related]

  • 20. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials.
    Hutton B, Fergusson D.
    Am J Clin Nutr; 2004 Dec 29; 80(6):1461-8. PubMed ID: 15585756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.